Data presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with type 2 diabetes achieved improved glycemic control, significantly lower rates of overall and nocturnal confirmed hypoglycemia for the full trial period, and a significantly lower rate of severe hypoglycemia during the maintenance period (defined as week 16 onwards) with Ryzodeg compared to biphasic insulin aspart 30, both administered twice-daily.
Ryzodeg is the first combination of two distinct insulin analogues, Tresiba (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid (insulin aspart), in the ratio of 70% and 30%, in one pen for people with type 2 diabetes.
“Type 2 diabetes is a progressive disease and many patients who are uncontrolled with basal insulin need to add mealtime insulin to achieve or maintain their glycemic targets over time. As Ryzodeg is a combination of two distinct insulins, a basal insulin with a long and steady action profile and a well-established mealtime insulin, it is a simple way for patients to add mealtime control with a reduced risk of overall and nocturnal confirmed, and severe hypoglycemia,” said lead investigator Gregory Fulcher, Royal North Shore Hospital, Sydney, Australia.
The multinational BOOST INTENSIFY PREMIX 1 trial was a 26-week, randomized, controlled open-label, treat-to-target trial comparing the efficacy and safety of Ryzodeg® and biphasic insulin apart 30, both administered twice-daily with or without oral anti-diabetic drugs in adult patients with type 2 diabetes previously treated with premixed or self-mixed insulin either once- or twice-daily.
Date: December 3, 2013
Source: Novo Nordisk
Filed Under: Drug Discovery